A

Armata Pharmaceuticals Inc
AMEX:ARMP

Watchlist Manager
Armata Pharmaceuticals Inc
AMEX:ARMP
Watchlist
Price: 2.25 USD 7.14% Market Closed
Market Cap: 81.4m USD
Have any thoughts about
Armata Pharmaceuticals Inc?
Write Note

Armata Pharmaceuticals Inc
EPS (Diluted)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Armata Pharmaceuticals Inc
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
A
Armata Pharmaceuticals Inc
AMEX:ARMP
EPS (Diluted)
-$1
CAGR 3-Years
-6%
CAGR 5-Years
9%
CAGR 10-Years
49%
Abbvie Inc
NYSE:ABBV
EPS (Diluted)
$2
CAGR 3-Years
-12%
CAGR 5-Years
6%
CAGR 10-Years
2%
Gilead Sciences Inc
NASDAQ:GILD
EPS (Diluted)
$0
CAGR 3-Years
-75%
CAGR 5-Years
-47%
CAGR 10-Years
-34%
Amgen Inc
NASDAQ:AMGN
EPS (Diluted)
$7
CAGR 3-Years
-7%
CAGR 5-Years
-10%
CAGR 10-Years
2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
EPS (Diluted)
-$1
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
2%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
EPS (Diluted)
$40
CAGR 3-Years
-13%
CAGR 5-Years
16%
CAGR 10-Years
30%
No Stocks Found

Armata Pharmaceuticals Inc
Glance View

Market Cap
81.4m USD
Industry
Biotechnology

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Marina Del Rey, California and currently employs 72 full-time employees. The firm is focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The company has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The firm is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. The company is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The firm is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. The company has phage development to target other indications, including non-cystic fibrosis bronchiectasis, prosthetic joint infections and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.

ARMP Intrinsic Value
1.61 USD
Overvaluation 28%
Intrinsic Value
Price
A

See Also

What is Armata Pharmaceuticals Inc's EPS (Diluted)?
EPS (Diluted)
-1.2 USD

Based on the financial report for Jun 30, 2024, Armata Pharmaceuticals Inc's EPS (Diluted) amounts to -1.2 USD.

What is Armata Pharmaceuticals Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
49%

Over the last year, the EPS (Diluted) growth was -12%. The average annual EPS (Diluted) growth rates for Armata Pharmaceuticals Inc have been -6% over the past three years , 9% over the past five years , and 49% over the past ten years .

Back to Top